Afamelanotide is an FDA-approved prescription drug for a rare disease, administered by a healthcare professional. This page explains how that label structures dosing and why the structure looks the way it does. It is education about a medicine's design, not instructions, and it does not describe a self-administered regimen.
Overview
There is only one validated Melanotan I dosing framework, and it is unlike anything sold online: a single 16 mg bioresorbable implant, inserted subcutaneously above the anterior supra-iliac crest, once every two months (Scenesse label, DailyMed). No daily dose, no titration ladder, no loading phase, no syringe. Every consumer-facing figure describing milligrams per day belongs to a different practice with no clinical data behind it.
The approved dosing framework
The approved product is a solid, white to off-white, bioresorbable sterile rod roughly 1.7 cm long containing 16 mg of afamelanotide. A healthcare professional places it subcutaneously above the anterior supra-iliac crest using a dedicated implantation cannula, repeated every 2 months. The rod dissolves in the tissue and releases peptide over that interval.
In the pivotal trials this produced a total of five implants over 180 days in the European study and three over 270 days in the US study (Langendonk, Balwani et al., NEJM 2015).
These figures describe the label's structure, not a plan for any reader. Candidate selection, placement technique, and the required twice-yearly skin examinations belong to a prescribing clinician working from the full prescribing information.
Why an implant rather than a syringe
The delivery format is not a packaging decision; it is the dosing strategy. A melanocortin peptide in aqueous solution clears quickly, so producing sustained melanogenesis with injections would require frequent repeat dosing, with the peak-and-trough exposure pattern that goes with it. A bioresorbable rod converts that into one controlled placement releasing peptide gradually across 60 days.
Two practical consequences follow. First, milligram totals are not comparable across formats: 16 mg released slowly over two months is a different pharmacological event from 16 mg injected. Second, the interval was chosen so that a clinician sees the patient every two months — which is also when the pigmentary surveillance the label requires can happen.
Where the online numbers come from
Figures circulating for injectable "MT-1" — typically a fraction of a milligram daily, escalating toward about 1 mg — come from tanning-community convention, not from any trial, regulator, or manufacturer. They are anecdotal in the strict sense: there is no published dose–response relationship for injected Melanotan I, no tolerability series, and no way to convert an implant's release profile into a daily injected amount.
The uncertainty compounds. Vial content accuracy is unverified, reconstitution volume changes concentration, and insulin-syringe unit markings are volume markings rather than dose markings — a well-documented source of tenfold errors. A 2017 review of unregulated α-MSH analogue use lists precisely these uncertainties about preparation, administration and dosing as a defining feature of the gray market (Habbema et al., Int J Dermatol 2017).
What the clinical setting adds
Comparing the two situations isolates what supervision actually contributes. The approved route delivers a verified quantity of a verified molecule, placed by a trained person, on a schedule tied to a monitoring visit, in a patient whose diagnosis justifies the exposure. The unregulated route keeps the pharmacology — including its effect on moles and freckles — and drops all four.
For what the approved drug was shown to do, see Melanotan I benefits; for the labelled adverse-reaction rates, see side effects and safety context.